Eyepoint Pharmaceuticals (NASDAQ:EYPT) Lowered to Hold Rating by Royal Bank Of Canada

Royal Bank Of Canada lowered shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) from a moderate buy rating to a hold rating in a report released on Monday morning,Zacks.com reports.

Other equities research analysts have also issued reports about the company. Citigroup decreased their target price on Eyepoint Pharmaceuticals to $17.00 and set a “buy” rating for the company in a research report on Tuesday. Stifel Nicolaus initiated coverage on shares of Eyepoint Pharmaceuticals in a report on Thursday, July 16th. They issued a “buy” rating and a $40.00 price target on the stock. Guggenheim restated a “buy” rating and set a $68.00 price target on shares of Eyepoint Pharmaceuticals in a research report on Wednesday, June 24th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Eyepoint Pharmaceuticals in a report on Monday. Finally, Jefferies Financial Group lowered their price objective on shares of Eyepoint Pharmaceuticals to $8.00 and set a “buy” rating on the stock in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Eyepoint Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $28.11.

Eyepoint Pharmaceuticals Stock Up 12.3%

EYPT stock opened at $5.47 on Monday. The firm has a market cap of $471.57 million, a PE ratio of -1.46 and a beta of 1.76. The business has a 50 day moving average of $12.97 and a 200-day moving average of $13.55. Eyepoint Pharmaceuticals has a 12-month low of $3.95 and a 12-month high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%.The business had revenue of $0.51 million for the quarter, compared to the consensus estimate of $0.45 million. On average, research analysts expect that Eyepoint Pharmaceuticals will post -3.6 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. California State Teachers Retirement System increased its stake in Eyepoint Pharmaceuticals by 20.6% in the 4th quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock worth $85,000 after acquiring an additional 794 shares during the last quarter. RWC Asset Management LLP boosted its position in shares of Eyepoint Pharmaceuticals by 6.4% during the 4th quarter. RWC Asset Management LLP now owns 17,235 shares of the company’s stock valued at $315,000 after acquiring an additional 1,040 shares during the last quarter. MCF Advisors LLC boosted its position in shares of Eyepoint Pharmaceuticals by 8.3% during the 4th quarter. MCF Advisors LLC now owns 14,921 shares of the company’s stock valued at $273,000 after acquiring an additional 1,149 shares during the last quarter. Raymond James Financial Inc. grew its holdings in shares of Eyepoint Pharmaceuticals by 11.0% during the second quarter. Raymond James Financial Inc. now owns 11,900 shares of the company’s stock worth $112,000 after purchasing an additional 1,177 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Eyepoint Pharmaceuticals by 51.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock worth $74,000 after purchasing an additional 1,358 shares in the last quarter. 99.41% of the stock is currently owned by hedge funds and other institutional investors.

Eyepoint Pharmaceuticals News Summary

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: Citigroup maintained a Buy rating while lowering its price target to $17, implying substantial potential upside from current levels. Jefferies also retained a Buy rating, with an $8 target. Benzinga analyst coverage
• Positive Sentiment: Although DURAVYU missed the full-study primary endpoint, EyePoint said the drug was non-inferior to aflibercept in an ad hoc analysis excluding an asymmetric group of patients whose vision loss was unrelated to wet AMD. The trial also showed a 42% reduction in treatment burden, durable disease control, supplement-free treatment rates and a favorable redosing safety profile. EyePoint LUGANO trial announcement
• Neutral Sentiment: Unusual options activity was reported, with traders purchasing 3,011 call contracts, about 19% above average call volume. This may reflect speculative expectations for a recovery but does not change the trial outcome.
• Neutral Sentiment: Trading in EYPT was temporarily halted for news before the trial results were released, underscoring the market sensitivity surrounding the announcement.
• Negative Sentiment: The full LUGANO dataset missed the primary endpoint, triggering a roughly two-thirds collapse in the stock and raising questions about DURAVYU’s regulatory path and commercial prospects. The result was widely described as a late-stage trial failure. Reuters trial report
• Negative Sentiment: Analyst sentiment became more cautious: Cantor Fitzgerald downgraded EYPT to Neutral, while Chardan, RBC, JPMorgan and HC Wainwright maintained neutral or sector-perform views. Chardan cut its target to $5 from $65, and RBC and Chardan both set $5 targets, indicating limited near-term upside.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.